)
Invokana, a member of the new class of drugs known as sodium glucose co-transporter 2 (SGLT2) inhibitors, was approved in the USA as a single agent in March 2013.
DiabetesInControl – FDA Approves J&J’s Invokamet Combo (SGLT-2 + Metformin)
Posted in Drugs